Economic Sanctions

Showing 1438 articles
Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

Rollins, Inc.: The Quiet Compounders in Pest Control

Amid market volatility, Rollins, Inc. (NYSE: ROL) represents a compelling case for stability. This analysis explores the pest control leader's resilient business model, built on recurring revenue and disciplined growth, which has delivered exceptional long-term returns for shareholders.

Business

MasTec's Growth Engine Faces a Cost Test: Can Margins Hold the Line?

Despite a stellar share price run, MasTec's earnings quality is under scrutiny as persistent margin pressures from supply chain strains and strategic growth investments challenge its financial resilience. Investors are watching to see if management can steer the infrastructure giant toward more sustainable profitability.

Business

FedEx CEO Charts Cautious Path on Robotics, Bets Big on AI for Global Network

While aggressively deploying AI across its vast logistics network, FedEx is taking a measured, pilot-stage approach to warehouse automation and drones, CEO Raj Subramaniam tells The New York Times. The shipping giant, handling $2 trillion in global commerce, prioritizes scalable infrastructure over unproven robotics for its 17 million daily packages.